Live Breaking News & Updates on Versus Placebo|Page 1

Stay updated with breaking news from Versus placebo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines

Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding. ....

United States , Adempas Verquvo , Patritumab Deruxtecan , Robertm Davis , Daiichi Sankyo Biologics , Daiichi Sankyo , Human Health , Afferent Pharmaceuticals , Exchange Commission , Merck Co Inc , Restructuring Program , Moderna Inc , Drug Administration , Net Income Attributable To Merck Co Inc , Prometheus Biosciences Inc , Harpoon Therapeutics Inc , Orion Corporation , Imago Biosciences Inc , Statement Of Merck Co Inc , European Commission , Us Centers For Disease , Merck Co , Animal Health , Alliance Revenue , Accepted Accounting Principles , Companion Animal ,

FDA Approves Etrasimod for Moderately to Severely Active Ulcerative Colitis

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. ....

Michael Chiorean , European Medicines Agency , Center At Swedish Medical , Drug Administration , Swedish Medical , Marketing Authorization Application , Severely Active Ulcerative Colitis , Versus Placebo , Induction Therapy , Etrasimod Velsipity , Ulcerative Colitis ,

Horizon Therapeutics (HZNP) Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

Horizon Therapeutics (HZNP) Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massimo Filippi , Neuroimmunol Neuroinflamm , Maria Rocca , Orhan Aktas , Jeffrey Bennett , European Commission , Drug Administration , Brazilian Health Regulatory Agency , Research In Multiple Sclerosis , Association Of Cytokine , European Committee For Treatment , Horizon Therapeutics , European Committee , Multiple Sclerosis , Cytokine Proteins , Disease Activity , Receiving Inebilizumab Treatment , Long Term Comparative Efficacy , Open Label Extension Versus Azathioprine , Immunosuppressive Therapies , Versus Placebo , Matching Adjusted Indirect Comparison , Current Treatments , Long Term Effectiveness , Neuromyelitis Optica Spectrum Disorder , Hepatitisb Virus ,

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spe

Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Mu. ....

Massimo Filippi , Rachel Vann , Jeffrey Bennett , Maria Rocca , Neuroimmunol Neuroinflamm , Orhan Aktas , Tina Ventura , Research In Multiple Sclerosis , European Committee For Treatment , European Commission , Brazilian Health Regulatory Agency , Drug Administration , Association Of Cytokine , Product Communications , Horizon Therapeutics , European Committee , Multiple Sclerosis , Cytokine Proteins , Disease Activity , Receiving Inebilizumab Treatment , Long Term Comparative Efficacy , Open Label Extension Versus Azathioprine , Immunosuppressive Therapies , Versus Placebo , Matching Adjusted Indirect Comparison , Current Treatments ,